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The Centers for Disease Control and Prevention (CDC) estimates that about 8,000 deaths in the 
United States are caused by melanoma skin cancer each year. Melanoma has become the most 
lethal skin cancer over the past three decades. Immunotherapies were introduced to Melanoma 
patients in the 60’s, and Interferon Alpha (IFN α) is one of the mostly used drugs for 
immunotherapy. Previous studies showed that using IFN α-2b might increase the survival rate of 
patients with high-risk melanoma skin cancer. However, not all patients respond to 
immunotherapies. So ECOG 1697 (E1697) trial was performed to compare the effect of patients 
obtained four-week high-dose IFN-a2b and the control group. This project utilizes a subset of the 
E1697 patients to search for potential immune-related genes that are associated with the 
prognosis of patients with localized melanoma. Both SNP and gene level analysis were 
conducted. This study has important public health significance because it identifies genetic factors 
associated with prognosis of local melanoma, which may be used to guide the treatment of this 
subgroup of melanoma patients in the future. 
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1.0  INTRODUCTION 
1.1 MELANOMA 
1.1.1 General Introduction 
According to the American Cancer Society, of all cancers, skin cancer is by far the most 
common one. Melanoma is the deadliest type of skin cancer. Over the past three decades, 
melanoma has the fastest growth of incidence rate among all skin cancers. The Centers for 
Disease Control and Prevention (CDC) estimates that about 8,000 deaths in the United States are 
caused by melanoma skin cancer each year (Plescia, Protzel Berman, & White, 2011). The 
American Cancer Society estimates that in 2015, over 73,000 new melanoma cases will be 
diagnosed, and nearly 10,000 people are expected to die from it in the United States (American 
Cancer Society. Cancer Facts & Figures 2015). 
Melanoma incidence is higher in whites than in blacks and Asians, and increases as 
people age. However, it is also one of the most common cancers in young adults (Bleyer, O'leary, 
Barr, & Ries, 2006), especially young women. Ultraviolet (UV) light exposure is a major risk 
factor for most melanomas (Parkin, Mesher, & Sasieni, 2011). Other known risk factors include 
large numbers of moles, fair skin, family or personal history of skin cancers, and a weakened 
immune system. Signs of melanoma typically seen include a new spot on the skin, a spot that is 
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changing in size, shape, or color, and a spot that looks different from all of the other spots on 
skin (known as the ugly duckling sign). 
1.1.2 Immunotherapy 
The treatments of melanoma include surgery, immunotherapy, targeted therapy, chemotherapy, 
and radiation therapy. Early-stage melanomas are often treated with surgery, but late-stage 
melanomas require advanced treatments after surgery. These advanced melanomas are difficult 
to treat with radiation and chemotherapy. Over the past few years, melanoma treatment is 
gradually transformed from the traditional chemotherapy and radiation therapy to 
immunotherapy and targeted therapy.  
The human immune system is a collection of organs, special cells, and substances that 
play a protective role from infections and other diseases. Immune response has a strong impact 
on melanoma prognosis (Herrera-Gonzalez, 2013). Immunotherapies stimulate a patient’s own 
immune system with medicines to recognize and destroy the melanoma cancer cells. 
Immunotherapies were introduced to Melanoma patients in the 60’s. One of the 
commonly used drugs for immunotherapy is Interferon Alpha (IFN α). Interferon is a man-made 
copy of human protein. It helps the immune system to fight viral infections. Interferon Alpha-2b 
(IFN α-2b) treatment is often given as a shot under the skin. Studies showed that using IFN α-2b 
might increase the survival rate of people with high-risk melanoma skin cancer (Kirkwood et al., 
2004; Kirkwood et al., 1996).  
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1.1.3 Clinical Biomarker for Melanoma Patients on Immunotherapy 
A biomarker usually refers to a measurable substance in the body that may be associated with the 
risk or prognosis of a certain disease. In melanoma immunotherapy, previous immune-based 
cancer therapies have found several serum biomarkers that may play potential prognostic or 
diagnostic roles for melanoma (Tartour et al., 1994; Wittke et al., 1999). However, these studies 
have not completely resolved the issue as how well the patients respond to immunotherapies.  As 
a result, there is need to continue identifying immune biomarkers capable of predicting clinical 
responses (Disis, 2011). 
1.2 E1697 STUDY 
E1697 (ECOG 1697) is a randomized intergroup trial aimed to compare the effect of two 
treatment arms: (A) observations with no evidence of disease, (B) patients obtain four weeks 
high-dose IFN-a2b with no evidence of disease. The study was terminated for futility in Oct. 
2010.  
1.3 IMMUNOCHIP 
Immunochip is a customized Illumina Infinium single-nucleotide polymorphism (SNP) 
microarray. It contains close to 200,000 genetic markers drawn from genomic regions possibly 
associated with one or more immune-mediated disease. Deep replication of meta-genome-wide 
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association studies (GWASs), and fine mapping of GWAS loci were the two major goals of 
Immunochip research (Parkes, Cortes, van Heel, & Brown, 2013). 
Genetic association studies examine the association of genetic variants with a disease. 
Immunochip is a high-density SNP array that provides cost-effective genotyping of common and 
rare variants to fine-map the established immune-related loci. This is a powerful tool for 
immunogenetics gene mapping in identifying large numbers of genetic loci (Cortes & Brown, 
2011). 
1.4 GOAL OF THE STUDY 
The effects of immunotherapies have been shown in previous studies on patients with melanoma 
skin cancer. However, not all patients respond to immunotherapies. This study utilizes a subset 
of the E1697 patients to search for potential immune-related genes that are associated with the 
prognosis of patients on either one-month high dose IFN α-2b arm or the observation arm. Our 
results will provide insights for the mechanism of how the patients’ immune system affects the 
prognosis of melanoma and provide potential prognostic (and predictive) biomarkers for 
melanoma patients.  
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2.0  METHODS AND RESULTS 
2.1 STUDY SAMPLE 
This is a correlative study of E1697 (ECOG 1697), which is a phase III randomized trial to 
compare the efficacy of four weeks of treatment of high-dose IFN-a2b with the observation arm. 
The current analysis aimed to discover prognostic genetic markers of melanoma patients. The 
analysis set is a subset of data from E1697 trial, which contains 216 randomly selected subjects. 
Blood samples were obtained at the study entry, and Immunochip was used to genotype the 
patients.  
2.2 DATA 
2.2.1 Starting Files 
The SAS file, e1697_spore_29april15.sas7bdat, is the clinical data I got for the subset of E1697 
trail from the ECOG statistician, which contains the following variables: 
Column1: case (case number: ranges from 15080 to 36000) 
Column2: trtm (treatment: A=control group, B=4-week high-dose IFN-a2b group) 
Column3: sex (1=male, 2=female) 
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Column4: BRSLW_THICKNESS (tumor Breslow’s depth in millimeters) 
Column5: CLARK_LVL (Clark’s level) 
Column6: LDH_RS (Lactate dehydrogenase value) 
Column7: LDH_ULN (LDH upper limit of normal) 
Column8: PIG (Pigmentation: 1= amelanotic, 2= melanotic, -1= unknown) 
Column9: PS (ECOG Performance status) 
Column10: ULCER_YN (Ulceration: 1=no, 2=yes, -1=unknown) 
Column11: surv_y (survival years) 
Column12: rfs (relapse free survival years) 
Column13: rfs_ind (relapse free survival index: 1=event, 0=censored) 
Column14: surv_s (survival index: 1=event, 0=censored) 
Column15: age (age at diagnosis) 
ImmunoChip_GeneAnnotation.csv, is a file with gene annotation information. It contains 
197076 lines (SNPs) and 8 columns: 
Column 1: Name (rs number for SNP identifier) 
Column 2: Chr (Chromosome number) 
Column 3: Coordinate 
Column 4: GeneSymbol (abbreviation of gene name) 
Column 5: GeneLocation 
Column 6: ExonLocation 
Column 7: CodingStatus 




Plink was used to perform the Quality Control of the genotype data. Plink is an open-
source command-line network connection tool written by Simon Tatham. It is a whole genome 
association analysis toolset for performing a range of basic, large-scale analyses (Purcell et al., 
2007). The PLINK program and instructions can be found at 
http://pngu.mgh.harvard.edu/~purcell/plink/.  
2.2.3 Binary Files 
The original genotype data were in binary PED files. The BED file, Mel_IC.bed, held the actual 
genotype information. It was a compressed file, which cannot be viewed with a standard text 
editor as the FAM and BIM files. The FAM file, Mel_IC.fam, contained subject information. The 
first six columns of BED file are: 
Column1: Family ID 
Column2: Individual ID 
Column3: Paternal ID 
Column4: Maternal ID 
Column5: Sex (1=male, 2=female) 
Column6: Phenotype (-9=missing, 1=unaffected, 2=affected) 
The BIM file, Mel_IC.bim, is an extended MAP file with two columns of allele names. 
The order of the columns are arranged as followed: 
Column1: Chromosome 
Column2: SNP Name 
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Column3: Cytogenetic Distance (in centimeter) 
Column4: Physical Distance (bp) 
Column5: Allele 1 
Column6: Allele 2 
2.2.4 Quality Control 
In Genome-wide association studies (GWAS), the quality control (QC) procedure is a critical 
element to inspect and clean data by reducing both the number of individuals and the number of 
SNPs passed on to downstream analysis (Turner et al., 2011; Weale, 2010). Because hundreds of 
thousands of genotypes are generated in GWAS, the occurrence of unidentified genotyping error 
may lead to spurious results. 
2.2.4.1 Relationship Check 
Relationship check is used to identify and record discrepancies between pedigrees provided and 
relatedness inferred from the genotype data by estimating the coefficients of identity by descent 
(IBD) (Turner et al., 2011). 
SNPs with minor allele frequency (MAF) < 0.05 (a total of 20658 SNPs) were removed 
given the very limited sample size of the study, because they tend to have poorly behaved test 
statistics. 
./plink --bfile ../Mel_IC --maf 0.05 --genome --rel-check --genome-full 
--min 0.05 --noweb --out Mel_IC_relationcheck 
A list of heterozygous haploid genotypes was written to Mel_IC_relationcheck.hh file. 
Whole genome IBD information was written to Mel_IC_relationcheck.genome file.  
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 Figure 1. Relationship Check plot 
 
Figure 1 is a plot showing the information of relative pairs of individuals. Z0 and Z1 
denote the probability that individual1 and individual2 in a family share 0 or 1 allele at the 
marker locus. We expected to see all individual pairs on the diagonal. Figure 1 shows no specific 
pattern or weird points except for the unusual point near 0.00. This is consistent with the fact that 
all our subjects are not related to each other.  The unusual point shares sample IDs as follows: 
130624, 132789, 130777, 132879 
2.2.4.2 Missing Data Check 
We next checked the missing data by individual and by SNP. 
./plink --bfile ../Mel_IC --missing --noweb --out Mel_IC_misscheck 
./plink --bfile ../Mel_IC --het --noweb --out Mel_IC_misscheck 
Through the first command line above, missing data information by individual was 
written to Mel_IC_misscheck.imiss file, and missing data information by locus was written to 
Mel_IC_misscheck.lmiss file. The second command line above wrote the individual 
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heterozygosity information to Mel_IC_misscheck.het file to check individuals with outlying 
heterozygosity rate.  
 
Figure 2. Missing data check by individual 
 
The observed heterozygosity rate per individual is plotted on the x axis of Figure 2 and 
the proportion of missing SNPs per individuals is plotted on the y axis. Figure 2 indicated two 
samples (SS0016, SS0093) with high missing rate (proportion of sample missing > 0.05) at the 
top of the plot. 
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 Figure 3. Missing data check by SNP 
 
Figure 3 shows a histogram of the missing data rate. Most of the proportion of sample 
that is missing is close to 0.00. 
2.2.4.3 Population Structure Check 
Population stratification is the systematic difference in allele frequencies between 
subpopulations. Population stratification may introduce false positive results if not proper 
controlled. Population structure check is aimed to detect subpopulation structure of the study 
population using multidimensional scaling (MDS) on SNP genotype data (Turner et al., 2011). 
We chose the number of dimension to be 4.  
./plink --bfile ../Mel_IC --remove rm.list.txt --make-bed --noweb --out  
Mel_IC_removed 
./plink --bfile Mel_IC_removed --noweb --indep 50 5 1.01 
./plink --bfile Mel_IC_removed --extract plink.prune.in --make-bed --
noweb --out Mel_IC_pruned 
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./plink --bfile Mel_IC_pruned --maf 0.05 --noweb --out Mel_IC_popustra 
–genome 
./plink --bfile Mel_IC_pruned --maf 0.05 --noweb --out Mel_IC_mds --
read-genome Mel_IC_popustra.genome --cluster --mds-plot 4 
The MDS plots of the 4 dimensions are shown in Figure 4. In our study, what we 
expected to see is that all the plots are almost like residue plots instead of any specific structure 
or pattern, so that we would not treat population structure as a confounder. 
 
 
Figure 4. Population structure matrix 
 
Figure 4 demonstrated that, overall, there is no obvious population structures, except for a 
few data points. Therefore, separate population structure plots with individual IDs were made to 
find those outliers. 
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 Figure 5. Population structure plot between C1 and C2 
 
 
Figure 6. Population structure plot between C2 and C3 
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 Figure 7. Population structure plot between C1 and C3 
 
 
Figure 8. Population structure plot between C3 and C4 
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 Figure 9. Population structure plot between C2 and C4 
 
 
Figure 10. Population structure plot between C1 and C4 
 
All of the five population structure plots above indicate the following four outliers: 
130624, 130777, 132789, 132879 
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According to relationship check, missing data check and population structure check 
results, we finally decided to remove six samples (130624, 130777, 132789, 132879, SS0016, 
SS0093) from original data set after quality control process. 
2.3 CLINICAL FACTORS 
2.3.1 Model Selection 
Cox proportional hazard regression was used to check the important clinical factors that affect 
the prognosis of the patients. The data file used in the analysis is e1697_spore_29april15.csv, 
which contains the final clinical data of these patients provided by the ECOG statistician. 
Clinical factors investigated in the analysis included trtm, sex, age, BRSLW_THICKNESS, 
CLARK_LVL, LDH_RS, LDH_ULN, PIG, PS and ULCER_YN (details listed in 2.2.1). 
Relapse-free survival (RFS) was used as the endpoint of the analysis. 
Purposeful selection is a considerate method to select covariates in the regression model 
manually. It follows a slightly different logic to stepwise selection as proposed by Hosmer and 
Lemeshow (Hosmer Jr, Lemeshow, & Sturdivant, 2013). First, univariate analysis was 






Table 1. Univariate model of RFS 
Covariate Wald Test p-value 
Treatment (A/B) 0.71 
Sex (Male/Female) 0.18* 
Tumor Breslow’s Thickness 0.01* 
Clark’s Level 0.15* 
Lactate Dehydrogenase (LDH) Value 0.51 
LDH Upper Limit of Normal 0.29 
Pigmentation 0.20* 
Performance Status 0.79 
Ulceration (Yes/No) 0.26 
Age at Diagnosis 0.01* 
       *significant at α=0.2 level 
 
Five covariates had significant p-values at α=0.2. Following the steps of purposeful 
selection, a multivariable model with only two covariates, tumor Breslow’s thickness and age at 
diagnosis, were included the final model. Table 2 lists the parameter estimates and Wald test p-
values for covariates in the final model. 
 
Table 2. Multivariable model of RFS 
Covariate Parameter Estimate Wald Test p-value 
Tumor Breslow’s Thickness 0.801 0.036 
Age at Diagnosis 0.025 0.018 
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2.4 TEST FOR ASSOCIATION AT SNP LEVEL 
The GenABEL-package was used to conduct the SNP level analysis. This package performs an 
effective and powerful role in storing and handling GWAS data, as well as fast quality control 
procedures, testing of association, visualization of results, and easy interfaces to standard 
statistical and graphical procedures in R (Aulchenko, Ripke, Isaacs, & van Duijn, 2007). 
Cox proportional hazards models were fit for RFS using the GenABEL package. Table 3 
shows the results for the top 10 most significant associations, sorted by the Wald test p values. 
(Top 50 most significant association results are listed in appendix.) 
 
Table 3. Summary for top 10 most significant association results at SNP level  
SNP Chr Coordinate Gene* Location P value 
rs6944473 7 14326377 DGKB INTRON 1.42E-06 
rs10495124 1 217568816 LYPLAL1|LOC728510 INTERGENIC 1.82E-05 
imm_12_2178130 12 2178130 CACNA1C INTRON 3.96E-05 
seq-rs2784110 1 197047009 PTPRC|LOC100131234 INTERGENIC 5.50E-05 
rs17591522 1 217600391 LYPLAL1|LOC728510 INTERGENIC 5.98E-05 
rs11942401 4 188052244 FAT|ZFP42 INTERGENIC 6.27E-05 
rs6704463 1 217614448 LYPLAL1|LOC728510 INTERGENIC 7.18E-05 
rs2095403 1 62632898 ANKRD38|USP1 INTERGENIC 8.27E-05 
rs2839235 21 46625020 PCNT INTRON 8.30E-05 
rs3860187 10 49639139 WDFY4 INTRON 0.0001103 
*Gene on which the SNP is located. When the SNP is located in between two genes, it is denoted as 
GENE1|GENE2.  
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A Manhattan plot of the SNP level results is shown in Figure 11.  A Manhattan plot is a 
plot of the negative logarithm of the association p-value (-log10 P) for each single nucleotide 
polymorphism (SNP) against the genomic coordinates. We have one signal jumps above in 
chromosome 7. It seems to be very significant. But we are worried about this. This could be a 
sporadic positive or could be real because we don’t have much information around it. So this 
signal needs to be checked out. Usually, a peak similar to chromosome 1 is expected to see for 
detecting the signals in genetic association study. Overall, we did not find many genome-wide 
significant results, which is expected for our sample size. Because the smallest p-value (the 
greatest negative logarithm) shown in the Manhattan plot is on chromosome 7, and chromosome 
1 also has several small p-values, we also provided the chromosome level Manhattan plots for 
these two chromosomes (Figure 12) to see closely if they have some signals. 
 
 
Figure 11. Manhattan plot 
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Figure 12. Manhattan plot for Chromosome 1 and 7 
 
A Quantile-Quantile (QQ) plot of the SNP level analysis is shown in Figure 13. It plots 
the observed –log10 p-values against the expected –log10 p-values under the null model of no 
association. If all points fall on the diagonal line, then there is no association. It is expected that 
most of the SNPs, with the exception of a few, should be on the diagonal line. If most of the 
points deviate from the diagonal line, it is an indication that the observed association is spurious 
due to unknown underlying factors. In our case, no indication of inflated overall association was 
found.  
 
Figure 13. QQ plot 
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LocusZoom was used to plot the association results of the most significant SNPs. 
LocusZoom is a tool to plot the association results from GWAS, developed by Abecasis group. It 
is available at http://locuszoom.sph.umich.edu/locuszoom/. The purpose of these plots is to 






Figure 14. Regional plot of area surrounding interested SNPs of –log (P values) using LocusZoom 
2.5 TEST FOR ASSOCIATION AT GENE LEVEL 
Given the limited sample size, we also looked at the gene level analysis to improve power. Gene 
level analysis utilizes all the SNPs on (or near) the gene for the association test to improve the 
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power. Two methods were used for this analysis: the Sequence kernel association test (SKAT) 
(Lee et al., 2012; Lin et al., 2011) and the CoxKM (Cai, Tonini, & Lin, 2011; Lee et al., 2012). 
Both are kernel-based methods for gene set analysis. However, SKAT can only handle 
continuous and binary phenotype while CoxKM is designed for the time-to-event phenotype. For 
SKAT analysis RFS is dichotomized at 3 years.  
2.5.1 SKAT 
Sequence kernel association test (SKAT), is a kernel-based test method to look for the 
association between variants and phenotype (Lee et al., 2012). It utilizes a kernel matrix to 
aggregate individual SNP score statistics and computes p-values at gene level. Top 10 signals 













Table 4. Top 10 SKAT results 
GENE Chr Start Stop p value 
DGKB 19 14136077 161585680 0.000147085 
LOC340268 4 9834067 185223182 0.000332623 
GABBR2 3 100274966 38086931 0.000336071 
FBXL17 2 107045500 34732070 0.000684611 
HTRA1 5 124216620 30136403 0.000800605 
DUSP10 22 219470464 1629929 0.000835814 
HLX 12 219074478 1635423 0.000836453 
FBLN7 12 112615980 32848649 0.000907298 
CPB2 23 45527945 84559380 0.000928026 
CTCFL 10 55500243 68295641 0.000944519 
 
2.5.2 CoxKM 
CoxKM-package is an R package to perform Cox kernel machine SNP-set association test for 
association between SNP-set and a right-censored survival outcome. It uses the kernel machine 
Cox regression framework and performs a score test to assess the overall effect of the interested 
genetic markers (Lin et al., 2011). Two different kernels, the IBS and linear kernel, were used in 
this analysis, and the top 10 results are listed below. The IBS kernel is a kernel function that 
incorporates the IBS information. The results of these two kernels are very similar (Table 5). 
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 Table 5. Top 10 coxKM results using IBS and linear kernel 
GENE n.marker.test n.indiv p.IBS Q.IBS df.IBS p.linear Q.linear df.linear 
HTRA1 2 205 1.00E-04 163.3571446 0.997232432 2.00E-04 318.2507069 1.0197953 
FBXO32 4 205 6.00E-04 51.8164787 3.526320773 4.00E-04 208.1382071 3.552179132 
FGF9 6 205 9.00E-04 53.7839697 3.490050315 0.0023 321.4549365 3.296177478 
HLX 9 205 0.0012 49.1513785 4.810549398 NA NA NA 
DUSP10 8 205 0.0012 55.69015018 4.034794788 3.00E-04 455.078092 4.084936 
SOCS6 16 205 0.0017 21.30837138 10.92939678 NA NA NA 
PEMT 4 205 0.0018 100.3035437 1.479564066 0.0021 401.2141747 1.492598419 
RAI1 4 205 0.0018 100.3035437 1.479564066 0.0021 401.2141747 1.492598419 
LOC642278 2 205 0.0019 133.8361564 1.066328026 0.001 267.6723128 1.034384141 
KCNK1 2 205 0.0019 68.19834591 1.636928436 NA NA NA 
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2.6 CROSS REFERENCES OF DIFFERENT ANALYSIS RESULTS 
2.6.1 Cross References of Gene Level Analysis 
After getting the separated gene level analysis results by using SKAT and coxKM methods, 
comparisons of the top 50 significant gene results were made to search for the overlap between 
these two methods. As shown in Table 6, there are 10 overlapping genes between the SKAT and 
coxKM analysis results.
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 Table 6. Cross references of SKAT and coxKM analysis results 
GENE Chr Start Stop n.marker.test p.value.IBS p.value.linear p value.SKAT 
HTRA1 5 124216620 30136403 2 1.00E-04 2.00E-04 0.000800605 
DUSP10 22 219470464 1629929 8 0.0012 3.00E-04 0.000835814 
HLX 12 219074478 1635423 9 0.0012 NA 0.000836453 
FBLN7 12 112615980 32848649 2 0.0042 0.0087 0.000907298 
ULK4 4 41834977 92844857 7 0.0089 0.0091 0.001026475 
LOC642278 4 556195 241014568 2 0.0019 0.001 0.003086166 
C20orf19 17 20735221 150859452 3 0.0023 0.0024 0.003348033 
C20orf74 17 20735221 150859711 3 0.0023 0.0024 0.003348033 
PEMT 20 17420920 159311566 4 0.0018 0.0021 0.007846131 
RAI1 18 17478733 159295042 4 0.0018 0.0021 0.007846131 
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 2.6.2 Cross References between Gene and SNP Level Analysis 
We were also interested to see if some overlapping results would happen between the gene level 
and SNP level analysis results. Comparisons between the top 50 significant gene results and top 
50 SNP level results were made. There are 3 overlapping genes between coxKM and SNP level 
analysis results (shown in Table 7), and only 1 overlapping gene between SKAT and SNP level 
analysis results (shown in Table 8). 
 
Table 7. Cross references of SKAT and SNP level analysis results 
GENE Chr SNP* SNP.Coordinate GeneLocation p.value.SNP p.value.SKAT 
DGKB 7 rs6944473 14326377 INTRON 1.42E-06 0.000147085 
*SNP is from the SNP level analysis 
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 Table 8. Cross references of coxKM and SNP level analysis results 






PLEKHG5 1 rs2986738 6470257 INTRON 0.000382766 2 0.0046 0.005 
LOC100132924 10 rs9629920 49629651 INTRON 0.000113517 5 0.0055 0.0069 
LOC100131234 1 seq-rs10800590 197042798 INTERGENIC 0.000221863 231 0.0087 0.0066 
*SNPs are from the SNP level analysis 
29 
3.0  DISCUSSION AND FUTURE WORKS 
3.1 GENERAL DISCUSSION 
A total of 205 subjects passed QC and were included in the analysis. The total number of events 
in these 205 subjects is 61, which is rather small given the large number of SNPs (197076) 
tested. Thus, the statistical power for this analysis is extremely low. This exploratory analysis 
aims to generate a top rank list of genes to be followed up by larger studies. Thus, the p-values of 
the tests are not to be taken literally, rather, as a way of ranking the top hits. Different methods 
are used to confirm and complement each other.  
In cancer research, OS is generally a more solid endpoint than RFS. The latter is 
subjected to the interval length of follow up. However, due to too few events in OS (32), we 
focused on the analysis using RFS as the phenotype.  
To avoid bias and improve accuracy in our analysis, we first investigated the potential 
clinical factors that are associated with RFS in our study population. After model selection, two 
covariates of interest, Breslow’s thickness and age at diagnosis, were left in the final. These two 
factors were controlled for in all of the following analyses. 
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3.2 SIGNIFICANT SIGNALS 
Association tests were performed at two different levels. At SNP level, CoxPH models 
implemented in GenABEL-package were used. LocusZoom plots of 4 of the top hits, rs6944473, 
rs10495124, rs13221118 and rs2839235, were generated. We were not able to plot three other 
SNPs of interest because they are not assigned rs-numbers. SNP rs6944473 has a strong signal. 
However, the SNPs nearby do not seem to have strong association with the RFS thus we do not 
observe a typical “peak” as we usually see in a positive signal of a GWAS.  Therefore, it could 
be a false positive. One possible cause of this could be genotype error. However, we are not able 
to check this because we do not have the raw data. We plotted the RFS plot by genotype of this 
SNP (Figure 15) to see if CoxPH is appropriate for the SNP. As shown in Figure 15 (I), the 
hazards between different genotype groups are proportional, although, the homozygous minor 
allele group has only 1 subject. We combined the subjects with minor allele together, as shown 
in Figure 15 (II), and applied log rank test. We obtained a significant p-value of 3.5E-7. 
Therefore, if this SNP is correctly genotyped, then it appears to be a significant predictor of RFS 
in our cohort. Further investigation of this result is needed.  
 
Figure 15. Kaplan-Meier curves of RFS by rs6944473 genotype 
(I. by genotype number, II. by genotype group) 
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At the gene level, two different kernel-based methods were used to test for association. 
CoxKM was used to test the association at gene level using the RFS as the phenotype. The 
SKAT was applied to a dichotomized (at 3 year) RFS endpoint. Both are kernel-based tests, and 
both in theory require much larger sample size than our study cohort. It is reassuring that when 
we compared the top 50 lists of the two methods, 10 overlapped, which is what we expected, 
because the phenotypes are largely correlated.  
When we cross-referenced the gene and SNP level analyses, the overlaps were very 
limited. DGKB showed up again in the SKAT analysis. The total number of SNPs on this gene 
included in the analysis for SKAT is 12. However, it is possible that the SKAT result is mostly 
driven by the one very significant SNP.   
3.3 FUTURE WORKS 
As discussed above, the results between the SNP and gene level analyses overlapped poorly. The 
analyses combined patients from both arms of the trial given that the trial is negative. However, 
at the molecular level, it is still possible that these two groups of patients responded differently. 
Thus, we plan to reanalyze the data stratified by patient treatment. This will further reduce the 
power of the study. However, we’ve experienced a similar situation where the subgroup analysis 
gave us more consistent results.  
In consulting with a geneticist, we will work with the PI of the study and try to 
understand the biological function of the top hits. A validation of the genotyping of potential 
signals using a targeted platform, e.g. the Sequenome chip, will further strengthen the results of 
this analysis. 
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APPENDIX A: ADDITIONAL TABLES 
Table 9. Summary for top 50 most significant association results at SNP level  
SNP Chr Coordinate GeneSymbol* Location P value 
rs6944473 7 14326377 DGKB INTRON 1.42E-06 
rs10495124 1 217568816 LYPLAL1|LOC728510 INTERGENIC 1.82E-05 
imm_12_2178130 12 2178130 CACNA1C INTRON 3.96E-05 
seq-rs2784110 1 197047009 PTPRC|LOC100131234 INTERGENIC 5.50E-05 
rs17591522 1 217600391 LYPLAL1|LOC728510 INTERGENIC 5.98E-05 
rs11942401 4 188052244 FAT|ZFP42 INTERGENIC 6.27E-05 
rs6704463 1 217614448 LYPLAL1|LOC728510 INTERGENIC 7.18E-05 
rs2095403 1 62632898 ANKRD38|USP1 INTERGENIC 8.27E-05 
rs2839235 21 46625020 PCNT INTRON 8.30E-05 
rs3860187 10 49639139 WDFY4 INTRON 0.0001103 
rs9629920 10 49629651 LOC100132924 INTRON 0.000113517 
imm_12_2187865 12 2187865 CACNA1C INTRON 0.000113531 
rs9309074 2 41821802 SLC8A1|LDHAL3 INTERGENIC 0.000118057 
imm_16_31279175 16 31279175 ITGAX CODING 0.000147564 
seq-rs10800591 1 197063314 PTPRC|LOC100131234 INTERGENIC 0.000185575 
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seq-rs12406470 1 197062743 PTPRC|LOC100131234 INTERGENIC 0.000185575 
seq-rs6427752 1 197062012 PTPRC|LOC100131234 INTERGENIC 0.000185575 
1kg_10_59547220 10 59547220 ZWINT|IPMK INTERGENIC 0.000207381 
seq-rs10800590 1 197042798 PTPRC|LOC100131234 INTERGENIC 0.000221863 
rs2226007 1 161860160 NUF2|LOC729952 INTERGENIC 0.00026407 
rs13221118 7 156493383 MNX1 INTRON 0.000289407 
rs7837005 8 72161586 XKR9|EYA1 INTERGENIC 0.000307944 
imm_1_67442201 1 67442201 IL23R INTRON 0.000330605 
rs10845202 12 10726132 STYK1|CSDA INTERGENIC 0.000352037 
rs270793 8 56012168 LOC100128419|XKR4 INTERGENIC 0.000354308 
rs6927768 6 170708910 TBP INTRON 0.000361202 
rs2986738 1 6470257 PLEKHG5 INTRON 0.000382766 
imm_9_138290709 9 138290709 QSOX2|DKFZP434A062 INTERGENIC 0.000421789 
rs1979302 18 55002156 SEC11C|GRP INTERGENIC 0.000452031 
rs12146041 1 173368784 TNN INTRON 0.000454158 
rs1156956 8 71917592 XKR9|EYA1 INTERGENIC 0.000471323 
rs7845516 8 71848376 XKR9|EYA1 INTERGENIC 0.000471323 
seq-rs2784114 1 197037793 PTPRC|LOC100131234 INTERGENIC 0.000486758 
rs12153520 5 130446033 CHSY-2|HINT1 INTERGENIC 0.00049527 
rs9262632 6 31132787 HCG22 UTR 0.000521266 
rs2332094 14 69139425 LOC100130174|KIAA0247 INTERGENIC 0.000540284 
rs545152 1 96659092 LOC729977|LOC440595 INTERGENIC 0.000547392 
rs990648 11 79730135 ODZ4|MGC33846 INTERGENIC 0.000555701 
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Table 9 Continued
rs6864771 5 7850291 ADCY2 INTRON 0.000560977 
rs9923190 16 85014134 LOC732275|LOC283904 INTERGENIC 0.000570215 
rs11753208 6 31113411 LOC729792 INTRON 0.000602604 
rs12155783 8 72161680 XKR9|EYA1 INTERGENIC 0.000608692 
imm_22_38042260 22 38042260 RPL3 INTRON 0.000610902 
imm_1_195577864 1 195577864 CRB1 INTRON 0.00063566 
rs7768644 6 31110080 LOC729792 INTRON 0.000692246 
rs7733977 5 130466000 CHSY-2|HINT1 INTERGENIC 0.000712495 
1kg_2_43478582 2 43478582 THADA INTRON 0.000758235 
rs9283781 5 82103862 LOC92270|TMEM167 INTERGENIC 0.000761276 
imm_12_2194668 12 2194668 CACNA1C INTRON 0.000761736 
imm_9_138290450 9 138290450 QSOX2|DKFZP434A062 INTERGENIC 0.0008274 




Table 10. Top 50 SKAT results 
GENE Chr Start Stop p value 
DGKB 19 14136077 161585680 0.000147085 
LOC340268 4 9834067 185223182 0.000332623 
GABBR2 3 100274966 38086931 0.000336071 
FBXL17 2 107045500 34732070 0.000684611 
HTRA1 5 124216620 30136403 0.000800605 
DUSP10 22 219470464 1629929 0.000835814 
HLX 12 219074478 1635423 0.000836453 
FBLN7 12 112615980 32848649 0.000907298 
CPB2 23 45527945 84559380 0.000928026 
CTCFL 10 55500243 68295641 0.000944519 
ULK4 4 41834977 92844857 0.001026475 
ADAMTS2 12 178485124 10945296 0.001097248 
GABRA5 14 24573461 138614368 0.001109697 
GRB2 3 70823779 52366748 0.001656428 
DDHD1 5 52524755 70796945 0.001727406 
LOC645434 5 139880112 24206432 0.002133753 
KIAA0195 3 70915763 52191086 0.00217213 
BMP4 11 52693414 70783451 0.002432467 
LOC100131472 19 10233678 181965614 0.002537652 
LOC729112 17 122598338 30505819 0.002589555 
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LOC642278 4 556195 241014568 0.003086166 
FGF21 5 53951133 69333750 0.003108941 
GRIK4 2 119870238 30923014 0.003142867 
C20orf19 17 20735221 150859452 0.003348033 
C20orf74 17 20735221 150859711 0.003348033 
LOC100130010 4 12094704 167311824 0.003372483 
TMEM89 23 48633471 79449021 0.003482006 
VARS2 4 30990256 119147430 0.003965721 
MTMR2 13 95208901 41013631 0.004078789 
SPON1 22 13882056 162191705 0.00457111 
GINS3 13 56971665 67130788 0.00472719 
SH3MD4 2 108973688 34522053 0.004736383 
C10orf67 14 23654346 141102100 0.0051071 
SULT1A1 21 28517358 129249695 0.005224223 
LOC100132354 23 43866851 87430929 0.005596336 
ADRB2 5 148201190 22583965 0.006717942 
SH3TC2 5 148201190 22583965 0.006717942 
BCAT2 5 53953425 69312471 0.006810132 
FLJ44815 4 29723177 127285007 0.006961246 
COL7A1 23 48579063 79458866 0.00724393 
AK5 9 77498829 49458078 0.007419735 
CCL1 4 29710751 127300962 0.007768454 
C9orf11 14 27223272 132113876 0.007777693 
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PEMT 20 17420920 159311566 0.007846131 
RAI1 18 17478733 159295042 0.007846131 
SEMA3A 20 83166896 46044577 0.007899354 
TBX15 2 118685496 31104111 0.008055778 
ZNF516 3 71278968 51888761 0.008316658 
C11orf49 23 47011024 80133854 0.008337512 
LOC645000 4 60737084 61843768 0.008477575 
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Table 11. Top 50 coxKM results using IBS and linear kernel 
GENE n.marker.test n.indiv p.IBS Q.IBS df.IBS p.linear Q.linear df.linear 
HTRA1 2 205 1.00E-04 163.3571446 0.997232432 2.00E-04 318.2507069 1.0197953 
FBXO32 4 205 6.00E-04 51.8164787 3.526320773 4.00E-04 208.1382071 3.552179132 
FGF9 6 205 9.00E-04 53.7839697 3.490050315 0.0023 321.4549365 3.296177478 
HLX 9 205 0.0012 49.1513785 4.810549398 NA NA NA 
DUSP10 8 205 0.0012 55.69015018 4.034794788 3.00E-04 455.078092 4.084936 
SOCS6 16 205 0.0017 21.30837138 10.92939678 NA NA NA 
PEMT 4 205 0.0018 100.3035437 1.479564066 0.0021 401.2141747 1.492598419 
RAI1 4 205 0.0018 100.3035437 1.479564066 0.0021 401.2141747 1.492598419 
LOC642278 2 205 0.0019 133.8361564 1.066328026 0.001 267.6723128 1.034384141 
KCNK1 2 205 0.0019 68.19834591 1.636928436 NA NA NA 
C20orf74 3 205 0.0023 78.02869894 1.874982136 0.0024 234.0860968 1.868850054 
C20orf19 3 205 0.0023 78.02869894 1.874982136 0.0024 234.0860968 1.868850054 
IL1F7 5 205 0.0033 45.87091418 1.903022303 0.0039 233.7458099 1.898427645 
LOC729668 22 205 0.0034 52.51872205 2.941225234 0.0039 1151.468446 2.844106193 
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BACH2 207 205 0.0035 28.79968437 8.606043205 0.0038 5867.49402 9.217885776 
CCDC88C 3 205 0.0036 85.93053123 1.205689231 0.003 251.9361541 1.239301028 
RRM1 3 205 0.0042 43.02581801 2.757766733 0.004 129.077454 2.74399433 
FBLN7 2 205 0.0042 67.98504669 2.016110267 0.0087 113.9488161 1.904888143 
PLEKHG5 2 205 0.0046 52.66691091 1.779263457 0.005 105.3338218 1.786707106 
C14orf181 70 205 0.005 34.29378735 5.221603951 0.004 2370.634724 5.12025002 
UBLCP1 111 205 0.0051 23.36087174 7.906729142 0.0053 2628.336445 8.059648632 
MAP3K8 121 205 0.0052 28.06843994 7.416439869 0.0039 1151.468446 2.844106193 
CHODL 2 205 0.0053 69.87374076 1.844069232 0.0055 139.7474815 1.80580238 
LOC100132924 5 205 0.0055 42.50840709 2.032615732 0.0069 212.5420355 2.034380308 
IDE 10 205 0.0056 36.50485026 3.234346832 NA NA NA 
ACTN1 62 205 0.0058 32.7955529 5.2595226 0.0053 2006.406783 5.162854725 
LOC730134 6 205 0.0058 35.88389223 4.489042795 0.0065 215.3033534 4.380506614 
LOC100131866 64 205 0.0059 34.90505968 4.542110238 0.0054 2223.256908 4.695085661 
LOC100128781 56 205 0.006 40.62994815 3.530145757 0.0057 2269.892288 3.728449707 
CBLN2 20 205 0.0062 16.17112482 13.3626406 0.0071 321.3913423 13.22349141 
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PHLDB1 45 205 0.0063 37.48481044 4.380171538 0.0053 1715.572943 4.406236761 
FTHL7 12 205 0.0063 26.17782462 6.714230682 0.0023 321.4549365 3.296177478 
ADRA1B 78 205 0.0064 23.196342 9.132998512 0.0038 1875.790706 9.257734887 
MRPL36 2 205 0.007 36.04350296 1.093684329 0.006 75.62701289 1.082086459 
KIR3DL2 3 205 0.0071 56.49377593 2.033623651 0.0079 156.7243266 2.016101053 
CLEC2B 140 205 0.0074 16.91395194 12.56710791 0.0075 2374.514151 12.61887258 
LOC728727 11 205 0.0076 31.14237744 5.204061415 0.0087 345.1852147 5.254971518 
FLJ41046 8 205 0.0076 27.17208389 4.079984235 0.0068 217.1868471 4.156190183 
FLJ42418 8 205 0.0076 27.17208389 4.079984235 0.0068 217.1868471 4.156190183 
DLC1 6 205 0.0082 33.05230852 4.132508543 0.0053 205.4312161 4.239507095 
WFDC12 3 205 0.0082 61.92950098 1.099297828 0.0127 169.9468802 0.973506929 
RUNX2 2 205 0.0083 50.71762835 2.021478056 0.0083 101.4352567 1.954351493 
DSCAML1 3 205 0.0084 24.35274809 2.550270076 0.0081 73.05824427 2.579148 
DYRK2 145 205 0.0087 26.0997574 6.63316068 NA NA NA 
DIP2C 6 205 0.0087 37.83638328 3.841283055 0.0089 227.0182997 3.852243302 
LOC100131234 231 205 0.0087 19.27530844 9.438183814 0.0066 4473.958268 9.945299748 
41 
Table 11 Continued
FZD8 5 205 0.0089 36.69497966 3.091913567 0.0074 183.4748983 3.199695772 
ULK4 7 205 0.0089 70.15212838 1.488121134 0.0091 485.790286 1.467081239 
HLA-E 482 205 0.0092 28.35820247 5.175844034 0.0087 13783.93721 5.180179863 
TNR 2 205 0.0093 54.69729222 1.953768899 NA NA NA 
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APPENDIX B: R CODE 
### Quality Control ### 
###1.Relationship Check 
# Relationship check 
setwd("~/Dropbox/thesis/QC/relationcheck") 
relation <- read.table("Mel_IC_relationcheck.genome", header = T) 
head(relation) 
attach(relation) 
plot(Z0, Z1, col = RT, xlim = c(0, 1), ylim = c(0, 1), 
 main = "Relationship Check") 
with(relation, text(Z0[which(Z0 < 0.01)] + 0.05, 
Z1[which(Z0 < 0.01)], IID1[which(Z0 < 0.01)]), cex = 0.5) 
s <- relation[relation$Z0 < 0.1, ] 
t <- s$IID1 # 130624 132789 
u <- s$IID2 # 130777 132879
###2.Missing Data Check 
# Missing data check by individual 
setwd("~/Dropbox/thesis/QC/missingcheck") 
het <- read.table("Mel_IC_misscheck.het", header = T) 
miss <- read.table("Mel_IC_misscheck.imiss", header = T) 
het_miss <- merge(het, miss, by = c("FID", "IID")) 
# Calculate the observed heterozygosity rate 
Observed_het_rate <- (het_miss$N.NM. - het_miss$O.HOM.) / het_miss$N.NM. 
het.miss <- data.frame(het_miss, Observed_het_rate) 
head(het.miss) 
with(het.miss, plot(Observed_het_rate, F_MISS, xlim = c(0.1, 0.9), main = 
"Missing data check")) 
with(het.miss, text(Observed_het_rate[which(F_MISS > 0.05)] + 0.05, 
F_MISS[which(F_MISS > 0.05)], IID[which(F_MISS > 0.05)])) 
b <- het.miss[het.miss$F_MISS > 0.01, ] 
a <- b$IID # 15 sample IDs 
# SS0110, SS0137, SS0016, SS0025, SS0045_Repeat, SS0054_Repeat, 
SS0070_Repeat, SS0090_Repeat, SS0091_Repeat, SS0092_Repeat, 
SS0134_Repeat, SS0159_Repeat, SS0199_Repeat, SS0217_Repeat, SS0093 
b1 <- het.miss[het.miss$F_MISS > 0.05, ] 
a1 <- b1$IID # 2 sample IDs 
# SS0016, SS0093 
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# Missing data check by SNP 
lmiss <- read.table("Mel_IC_misscheck.lmiss", header = T) 
dim(lmiss) # 129903      5 
 
with(lmiss, hist(F_MISS, breaks = 100, xlim = c(0, 0.1))) 
abline(v = 0.05, col = "red", lty = 2) 
dim(lmiss[which(lmiss$F_MISS < 0.05), ]) # 129043      5 
 
###3.Population Structure Check 
 
# Population structure check 
setwd("~/Dropbox/thesis/QC/popustra") 
 




# plot matrix 
plot(mds[, c(-1, -2, -3)], main = "Population structure check") 
 
# make separate population structure plots to find outliers 
# C1-C2 
# add noise to separate overlapped points 
x = jitter(mds[, 4], factor = 500) 
y = jitter(mds[, 5], factor = 500) 
 
# make population structure check plot with individual IDs 
plot(x, y, main = "Population structure check", xlab = "C1", ylab = "C2") 
text(x, y, labels = IID, pos = 4, cex = 0.8) 
 
# C2-C3 
# add noise to separate overlapped points 
x1 = jitter(mds[, 5], factor = 500) 
y1 = jitter(mds[, 6], factor = 500) 
 
# make population structure check plot with individual IDs 
plot(x1, y1, main = "Population structure check", xlab = "C2", ylab = 
"C3") 
text(x1, y1, labels = IID, pos = 1, cex = 0.8) 
 
# C1-C3 
# add noise to separate overlapped points 
x2 = jitter(mds[, 4], factor = 500) 
y2 = jitter(mds[, 6], factor = 500) 
 
# make population structure check plot with individual IDs 
plot(x2, y2, main = "Population structure check", xlab = "C1", ylab = 
"C3") 
text(x2, y2, labels = IID, pos = 1, cex = 0.8) 
 
# C3-C4 
# add noise to separate overlapped points 
x3 = jitter(mds[, 6], factor = 500) 
y3 = jitter(mds[, 7], factor = 500) 
 
# make population structure check plot with individual IDs 
plot(x3, y3, main = "Population structure check", xlab = "C3", ylab = 
"C4") 




# add noise to separate overlapped points 
x4 = jitter(mds[, 5], factor = 500) 
y4 = jitter(mds[, 7], factor = 500) 
 
# make population structure check plot with individual IDs 
plot(x4, y4, main = "Population structure check", xlab = "C2", ylab = 
"C4") 
text(x4, y4, labels = IID, pos = 3, cex = 0.8) 
 
# C1-C4 
# add noise to separate overlapped points 
x5 = jitter(mds[, 4], factor = 500) 
y5 = jitter(mds[, 7], factor = 500) 
 
# make population structure check plot with individual IDs 
plot(x5, y5, main = "Population structure check", xlab = "C1", ylab = 
"C4") 








e1697 <- read.csv("e1697_spore_29april15.csv",header=T)   # 216 
head(e1697) 
 
# only include treatment A or B 
ab <- e1697[e1697$trtm=="A"|e1697$trtm=="B",]   # 216 obs, since e1697 
only include treatment A and B 
 
# change column names 
names(ab) 
colnames(ab)[13] <- "cens.RFS" 
colnames(ab)[14] <- "cens.OS" 
colnames(ab)[4] <- "BRSLW" 
colnames(ab)[5] <- "CLARK" 
 
# calculate OS and RFS in days 
ab$OS.n <- ab$surv_y*365 
ab$RFS.n <- ab$rfs*365 
 
# dichotomize BRSLW using cutoff=2 
sum(ab$BRSLW<=2)   # 52 
sum(ab$BRSLW>2)   #164 
ab[ab$BRSLW<=2,]$BRSLW <- 0 






surv <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ strata(trtm) + sex 
+ BRSLW + CLARK + LDH_RS + LDH_ULN + PIG + PS + ULCER_YN + age, data = 
pheno) 
summary(surv)   # p=0.02, Rsquare= 0.085 
 
# univariable models 
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surv.trtm <- survfit(Surv(time=pheno$RFS.n, event=cens.RFS) ~ trtm, data = 
pheno) 
plot(surv.trtm) 
surv.trtm.cox <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ trtm, data 
= pheno) 
summary(surv.trtm.cox)   # p=0.71 
 
surv.sex <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ sex, data = 
pheno) 
summary(surv.sex)   # p=0.18* <0.2 
 
surv.brslw <- survfit(Surv(time=pheno$RFS.n, event=cens.RFS) ~ BRSLW, data 
= pheno) 
plot(surv.brslw) 
surv.brslw.cox <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ BRSLW, 
data = pheno) 
summary(surv.brslw.cox)   # p=0.01* <0.2 
 
surv.clark <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ CLARK, data = 
pheno) 
summary(surv.clark)   # p=0.15* <0.2 
 
surv.ldh <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ LDH_RS, data = 
pheno) 
summary(surv.ldh)   # p=0.51 
 
surv.ldhu <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ LDH_ULN, data 
= pheno) 
summary(surv.ldhu)   # p=0.29 
 
surv.pig <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ PIG, data = 
pheno) 
summary(surv.pig)   # p=0.195* <0.2 
 
surv.ps <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ PS, data = 
pheno) 
summary(surv.ps)   # p=0.79 
 
surv.ulcer <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ ULCER_YN, 
data = pheno) 
summary(surv.ulcer)   # p=0.26 
 
surv.age <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ age, data = 
pheno) 
summary(surv.age)   # p=0.006* <0.2 
 
# fit a multivariable model containing all variables significant in the 
univariable analysis at p<0.2 level 
# sex, BRSLW, CLARK, PIG, age 
surv.multi <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ sex + BRSLW + 
CLARK + PIG + age, data = pheno) 
summary(surv.multi)   # p=0.004 
# Wald test p-values: sex=0.57, BRSLW=0.05*, CLARK=0.33, PIG=0.12, 
age=0.03* 
 
# delete sex and refit the multivariable model 
# BRSLW, CLARK, PIG, age 
surv.multi1 <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ BRSLW + 
CLARK + PIG + age, data = pheno) 
summary(surv.multi1)   # p=0.002 
# Wald test p-values: BRSLW=0.05*, CLARK=0.34, PIG=0.13, age=0.017* 
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# estimates of coefficients are virtually unchanged 
 
# delete CLARK and refit the multivariable model 
# BRSLW, PIG, age 
surv.multi2 <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ BRSLW + PIG 
+ age, data = pheno) 
summary(surv.multi2)   # p=0.0013 
# Wald test p-values: BRSLW=0.03*, PIG=0.12, age=0.012* 
# estimates of coefficients are virtually unchanged 
 
# delete PIG and refit the multivariable model 
# BRSLW, age 
surv.multi3 <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ BRSLW + age, 
data = pheno) 
summary(surv.multi3)   # p=0.0014 
# Wald test p-values: BRSLW=0.0355*, age=0.0176* 
# estimates of coefficients are virtually unchanged 
 
 
# add ULCER_YN and refit the multivariable model to see if ULCER_YN 
becomes significant 
# BRSLW, age, ULCER_YN 
surv.multi4 <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ BRSLW + age 
+ ULCER_YN, data = pheno) 
summary(surv.multi4)   # p=0.002 
# Wald test p-values: BRSLW=0.03*, age=0.03*, ULCER_YN=0.26 
# ULCER_YN is not significant, so no need to add it 
 
# add LDH_ULN and refit the multivariable model to see if LDH_ULN becomes 
significant 
# BRSLW, age, LDH_ULN 
surv.multi5 <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ BRSLW + age 
+ LDH_ULN, data = pheno) 
summary(surv.multi5)   # p=0.003 
# Wald test p-values: BRSLW=0.03*, age=0.02*, LDH_ULN=0.27 
# LDH_ULN is not significant, so no need to add it 
 
# add LDH_RS and refit the multivariable model to see if LDH_RS becomes 
significant 
# BRSLW, age, LDH_RS 
surv.multi6 <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ BRSLW + age 
+ LDH_RS, data = pheno) 
summary(surv.multi6)   # p=0.003 
# Wald test p-values: BRSLW=0.035*, age=0.017*, LDH_RS=0.47 
# LDH_RS is not significant, so no need to add it 
 
# add trtm and refit the multivariable model to see if trtm becomes 
significant 
# BRSLW, age, trtm 
surv.multi7 <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ BRSLW + age 
+ trtm, data = pheno) 
summary(surv.multi7)   # p=0.004 
# Wald test p-values: BRSLW=0.0364*, age=0.0175*, trtm=0.71 
# trtm is not significant, so no need to add it 
 
# add PS and refit the multivariable model to see if PS becomes 
significant 
# BRSLW, age, PS 
surv.multi8 <- coxph(Surv(time=pheno$RFS.n, event=cens.RFS) ~ BRSLW + age 
+ PS, data = pheno) 
summary(surv.multi8)   # p=0.004 
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# Wald test p-values: BRSLW=0.035*, age=0.0167*, PS=0.69 
# PS is not significant, so no need to add it 
 
### final model only contains BRSLW and age 
 
 




### Test for Association at SNP Level ### 
 








# prepare for creating genotype data 
ab <- read.csv("model_brsage.csv", header=T)   # 216 




header=T)   # 299 
names(Mel2013) 
Mel2013 <- Mel2013[, c(1,5,39,57)] 
 
data <- merge(ab, Mel2013, by="SEQ_NUMBER")   # 215 




id <- data[, c(20,18)] 
 














pheno <- data[, c(18,16,14,17,13,2:10,15)] 
head(pheno)   # 215 obs, 15 var 
colnames(pheno)[1] <- "id" 
 




# since pheno.txt has 215 obs, but Clean-Mel_IC.raw only has 205 obs,  
# pheno.txt needs to be checked line-by-line 
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pheno.clean <- read.table("pheno-clean.txt", header=T)   # 205 obs 
# SS0045, SS0054, SS0070, SS0090, SS0091, SS0092, SS0134, SS0159, SS0199, 
SS0217 were removed 
 
# count number of RFS events and OS events 
event <- pheno.clean[pheno.clean$cens.RFS == 1, ]   # 61 event, 144 censor 
event_OS <- pheno.clean[pheno.clean$cens.OS == 1, ]   # 61 event, 144 
censor 
 
# change sex from 1/2 (1 = male, 2 = female) to 0/1 (0=female and 1=male) 
pheno.clean$sex <- ifelse(pheno.clean$sex == 2, pheno.clean$sex <- 0, 
pheno.clean$sex <- 1) 




# use GenABEL package 
data <- load.gwaa.data(phe="pheno-clean.txt", gen="Clean-Mel_IC.raw", 
force=TRUE) 
 
# run Cox proportional hazards models 
 
cox.RFS <- mlreg(GASurv(RFS.n, cens.RFS) ~ 1, data) 
 
CHR = data@gtdata@chromosome 
BP = data@gtdata@map 
 
RFS.7 <- cox.RFS@ results[which(cox.RFS@ results$ P1df < 10^(-7)), 
c("effB", "se_effB", "chi2.1df", "P1df" )] 
RFS.4 <- cox.RFS@ results[which(cox.RFS@ results$ P1df < 10^(-4)), 
c("effB", "se_effB", "chi2.1df", "P1df" )] 
dim(RFS.7)   # 0 obs, 4 var 
dim(RFS.4)   # 4 obs, 4 var 
 
RFS.all <- cox.RFS@ results[ , c("effB", "se_effB", "chi2.1df", "P1df" )] 
SNP = row.names(RFS.all) 
RFS.all = data.frame(SNP,CHR,BP,RFS.all) 
 
write.table(RFS.all, sep="\t", file="RFS.all.txt", row.names=FALSE) 
 
 
#--- QQ plot and manhattan plot ---# 
 
#-- plot RFS --# 
plot.RFS <- data.frame(CHR=data@gtdata@chromosome, BP=data@gtdata@map, 
P=cox.RFS@results$P1df) 
plot.RFS$CHR <- as.numeric(as.character(drop.levels(plot.RFS$CHR))) 
dim(plot.RFS)   # 108300 obs, 3 var 
head(plot.RFS) 
 
qq(plot.RFS$P, main="Q-Q plot for RFS") 
 
 
### Manhattan plot of cox.RFS and find the most significant association 
SNPs ### 
 
plot(cox.RFS, ylim=c(0,7), pch=19, main="Manhattan plot for RFS") 
 
bestHits <- descriptives.scan(cox.RFS, top=50)    





# adjust for BRSLW and age 
 
cox.RFS.brsage <- mlreg(GASurv(RFS.n, cens.RFS) ~ BRSLW + age, data) 
 
RFS.7.brsage <- cox.RFS.brsage@ results[which(cox.RFS.brsage@ results$ 
P1df < 10^(-7)), c("effB", "se_effB", "chi2.1df", "P1df" )] 
RFS.4.brsage <- cox.RFS.brsage@ results[which(cox.RFS.brsage@ results$ 
P1df < 10^(-4)), c("effB", "se_effB", "chi2.1df", "P1df" )] 
dim(RFS.7.brsage)   # 0, 4 
dim(RFS.4.brsage)   # 9, 4 
 
RFS.brsage.all <- cox.RFS.brsage@ results[, c("effB", "se_effB", 
"chi2.1df", "P1df" )] 
RFS.brsage.all = data.frame(SNP,CHR,BP,RFS.brsage.all) 
 
write.table(RFS.brsage.all, sep="\t", file="RFS.brsage.all.txt", 
row.names=FALSE) 
 
#--- QQ plot and manhattan plot ---# 
 
#-- plot RFS --# 




dim(plot.RFS.brsage)   # 108300 obs, 3 var 
head(plot.RFS.brsage) 
 
qq(plot.RFS.brsage$P, main="Q-Q plot for RFS.brsage") 
 
 
### Manhattan plot of cox.RFS and find the most significant association 
SNPs ### 
plot(cox.RFS.brsage, ylim=c(0,6), pch=19, main="Manhattan plot for 
RFS.brsage") 
 
bestHits.brsage <- descriptives.scan(cox.RFS.brsage,top=50)    




### Manhattan plot of cox.RFS but only plot Chr1 and Chr7 ### 
plot.RFS.brsage.1.7 <- plot.RFS.brsage[plot.RFS.brsage$CHR == 1 | 
plot.RFS.brsage$CHR == 7, ]   # 15799 
 
### find gene annotation for bestHits.brsage 
bestHits.brsage. <- data.frame(rownames(bestHits.brsage), bestHits.brsage)   
# make row.names as a new column 
colnames(bestHits.brsage.)[1] <- "Name" 
 
anno <- read.table("ImmunoChip_GeneAnnotation.txt", header=T, fill=T)   # 
197076 
 






bestHits50 <- bestHits.brsage1[, c(1:5,10,18)] 
head(bestHits50) 
bestHits50 <- bestHits50[order(bestHits50$P1df), ] 
 
write.csv(bestHits50, file="bestHits50.csv", row.names=FALSE) 
 
 
### prepare file for LocusZoom 
plot.RFS.brsage1 <- data.frame(rownames(plot.RFS.brsage), plot.RFS.brsage)   
# make row.names as a new column 














#-- Genotype data 
tped <- read.table("Clean-Mel_IC.tped")   # 108300, 414 
colnames(tped)[2] <- "Name" 
 
anno <- read.table("ImmunoChip_GeneAnnotation.txt", header=T, fill=T)   # 
197076, 8 
 




Interested.Gene <- merge[, c(1:5)]   # 108300, 5 
head(Interested.Gene) 
 
### delete X, Y chromosomes 
Interested.Gene <- Interested.Gene[Interested.Gene$Chr != "X" & 
Interested.Gene$Chr != "Y", ]   # 107816 
 
### modify INTERGENIC GeneSymbol into separated rows 
INTERGENIC <- Interested.Gene[Interested.Gene$GeneLocation == 
"INTERGENIC", ]   # 59381 
noINTERGENIC <- Interested.Gene[Interested.Gene$GeneLocation != 
"INTERGENIC", ]   # 48435 
 
INTERGENIC$GeneSymbol1 <- gsub("[|].+$", "", INTERGENIC$GeneSymbol) 
INTERGENIC$GeneSymbol2 <- gsub("^.+[|]", "", INTERGENIC$GeneSymbol) 




Intergenic1 <- INTERGENIC[, c(1,2,3,5,4)] 
Intergenic2 <- INTERGENIC[, c(1,2,3,6,4)] 
colnames(Intergenic1)[4] <- "GeneSymbol" 
colnames(Intergenic2)[4] <- "GeneSymbol" 
 
Interested_Gene <- rbind(Intergenic1, Intergenic2, noINTERGENIC)    
# 167197 
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Interested_Gene <- Interested_Gene[order(Interested_Gene$Coordinate), ] 
Interested_Gene2 <- Interested_Gene[order(-Interested_Gene$Coordinate), ] 
 
#write.csv(Interested_Gene, file="Interested_Gene.csv", row.names=FALSE) 
#write.csv(Interested_Gene2, file="Interested_Gene2.csv", row.names=FALSE) 
 
# Dichotomize RFS 
Dicho.RFS <- pheno$cens.RFS 
Dicho.RFS[pheno$RFS.n < 3*365 & pheno$cens.RFS == 1] <- 1 
Dicho.RFS[pheno$RFS.n > 3*365 & pheno$cens.RFS == 1] <- 0   
Dicho.RFS[pheno$RFS.n > 3*365 & pheno$cens.RFS == 0] <- 0 
Dicho.RFS[is.na(pheno$RFS.n)] <- NA 
table(Dicho.RFS) 
 
#-- Phenotype data 
pheno <- read.table("pheno-clean.txt", header = TRUE) 
 
#-- Code genotype as (0, 1, 2) 
hwe <- read.table("plink.hwe", header=T)   # 324900, 9 
hwe <- hwe[which(hwe$TEST == "ALL"), ]   # 108300, 9 
 
Minor.allele <- hwe$A1 
Major.allele <- hwe$A2 
 
Code0 <- paste(Major.allele, Major.allele, sep="_") 
Code1a <- paste(Major.allele, Minor.allele, sep="_") 
Code1b <- paste(Minor.allele, Major.allele, sep="_") 







Result.OS.IBS <- NULL 
Result.OS.linear <- NULL 
Result.RFS.IBS <- NULL 
Result.RFS.linear <- NULL 
 
unique1 <- unique(Interested_Gene$GeneSymbol) 
length(unique1)   #12384 
unique2 <- unique(Interested_Gene2$GeneSymbol) 
length(unique2)   #12384 
 
Gene.name <- NULL 
Chrom <- NULL 
Chr.pos <- NULL 
Number.SNP <- NULL 
Skat.Dicho.RFS <- NULL 
Skat.Dicho.OS <- NULL 
 
 
for(s in 1:length(unique1)){ 
  set.seed(1) 
   
  Chr <- Interested_Gene$Chr[which.max(Interested_Gene$GeneSymbol == 
unique1[s])] 
  Start <- Interested_Gene$Coordinate[which.max(Interested_Gene$GeneSymbol 
== unique1[s])] 




   
  Geno <- tped[which(tped$V1 == Chr & tped$V4 > Start & tped$V4 < Stop), ] 
   
  if(dim(Geno)[1] == 0){ 
    Result.OS.IBS <- rbind(Result.OS.IBS, c(NA, NA, 0, NA, NA)) 
    Result.OS.linear <- rbind(Result.OS.linear, c(NA, NA, 0, NA, NA)) 
    Result.RFS.IBS <- rbind(Result.RFS.IBS, c(NA, NA, 0, NA, NA)) 
    Result.RFS.linear <- rbind(Result.RFS.linear, c(NA, NA, 0, NA, NA)) 
  }   
 
  if(dim(Geno)[1] == 1){ 
    Result.OS.IBS <- rbind(Result.OS.IBS, c(NA, NA, 1, NA, NA)) 
    Result.OS.linear <- rbind(Result.OS.linear, c(NA, NA, 1, NA, NA)) 
    Result.RFS.IBS <- rbind(Result.RFS.IBS, c(NA, NA, 1, NA, NA)) 
    Result.RFS.linear <- rbind(Result.RFS.linear, c(NA, NA, 1, NA, NA)) 
  }  
 
  if(dim(Geno)[1] > 1){ 
    Gene.name <- c(Gene.name, 
as.character(unique(Interested_Gene$Name)[s])) 
    Chrom <- c(Chrom, Interested_Gene$Chr[s])    
    Chr.pos <- c(Chr.pos, Start) 
    Number.SNP <- c(Number.SNP, dim(Geno)[1]) 
     
    n = ((dim(Geno)[2]-4)/2) 
    genotype <- matrix(NA, nrow=dim(Geno)[1], ncol=n) 
    ind <- 5 
 
    for(i in 1:n){ 
      genotype[,i] <- paste(Geno[, ind], Geno[,ind+1], sep="_") 
      ind <- ind+2 
    } 
 
    genotype.012 <- genotype 
 
    for(i in 1:dim(genotype)[2]){ 
      genotype.012[which(genotype[,i] %in% Code0), i] <- 0 
      genotype.012[which(genotype[,i] %in% Code1a), i] <- 1 
      genotype.012[which(genotype[,i] %in% Code1b), i] <- 1  
      genotype.012[which(genotype[,i] %in% Code2), i] <- 2 
    } 
 
    table(genotype.012) 
 
    genotype.012 <- matrix(as.numeric(genotype.012), 
ncol=dim(genotype.012)[2]) 
    dim(genotype.012) 
    Z = t(genotype.012) 
     
     
    ### Dichotomize RFS with SKAT-O 
    obj <- SKAT_Null_Model(Dicho.RFS ~ 1, out_type="D") 
    Skat.Dicho.RFS <- c(Skat.Dicho.RFS, SKAT(Z, obj, 
method="optimal.adj")$p.value) 
     
    ### coxKM 
    fit <- coxKM(Z=t(genotype.012), U=pheno$OS.n, Delta=pheno$cens.OS, 
kernel="IBS") 
    Result.OS.IBS <- rbind(Result.OS.IBS, unlist(fit)) 
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    fit <- coxKM(Z=t(genotype.012), U=pheno$OS.n, Delta=pheno$cens.OS, 
kernel="linear") 
    Result.OS.linear <- rbind(Result.OS.linear, unlist(fit)) 
     
    Z <- matrix(t(genotype.012), ncol=dim(genotype.012)[1]) 
     
    fit <- coxKM(Z=Z, U=pheno$RFS.n, Delta=pheno$cens.RFS, kernel="IBS") 
    Result.RFS.IBS <- rbind(Result.RFS.IBS, unlist(fit)) 
     
    fit <- coxKM(Z=Z, U=pheno$RFS.n, Delta=pheno$cens.RFS, 
kernel="linear") 
    Result.RFS.linear <- rbind(Result.RFS.linear, unlist(fit)) 
     
  } 
} 
 
rownames(Result.OS.IBS) <- unique1 
rownames(Result.OS.linear) <- unique1 
rownames(Result.RFS.IBS) <- unique1 
rownames(Result.RFS.linear) <- unique1 
 
Gene <- Interested_Gene[!duplicated(Interested_Gene$GeneSymbol), ] 
Result.OS.IBS<- cbind(Result.OS.IBS, Gene) 
Result.OS.linear<- cbind(Result.OS.linear, Gene) 
Result.RFS.IBS<- cbind(Result.RFS.IBS, Gene) 
Result.RFS.linear<- cbind(Result.RFS.linear, Gene) 
 



















noDGKB <- read.table("Clean-Mel_IC_noDGKB.raw", header=T) 
 
pheno.clean <- read.table("pheno-clean.txt", header=T)   # 205 obs 
colnames(pheno.clean)[1] <- "IID" 
 
pheno.clean$RFS.year <- pheno.clean$RFS.n / 365 
 
DGKB_pheno <- merge(pheno.clean, noDGKB, by="IID") 
names(DGKB_pheno) 
 
# draw survival curve for the most significant SNP rs6944473 
library(survival) 
 
surv <- survfit(Surv(RFS.year, cens.RFS) ~ rs6944473_G, data = DGKB_pheno) 
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plot(surv, col=c("blue","red","green"), lty=1, xlab="Time(year)", 
ylab="Survival proportion") 
legend("topright", legend=c("0","1","2"), col=c("blue","red","green"), 
horiz=FALSE, y.intersp=0.9, bty='n', cex=0.8, lty=1, pt.cex = 1, 
title="Genotype number of minor allele:") 
mtext("I", side=3, line=1, at=3) 
 
table(DGKB_pheno$rs6944473_G)   # 0:185, 1:19, 2:1 
 
 
### dichotomize rs6944473_G as 0 and 1/2 because we only have 1 subject 
has 2 minor alleles 
Dicho <- DGKB_pheno$rs6944473_G 
Dicho[DGKB_pheno$rs6944473_G == 0] <- 0 
Dicho[DGKB_pheno$rs6944473_G == 1 | DGKB_pheno$rs6944473_G == 2] <- 1 
table(Dicho) 
 
DGKB_pheno1 <- cbind(DGKB_pheno, Dicho)   # 0:185, 1:20 
 
surv1 <- survfit(Surv(RFS.year, cens.RFS) ~ Dicho, data = DGKB_pheno1) 
 
plot(surv1, col=c("blue","red"), lty=1, xlab="Time(year)", ylab="Survival 
proportion") 
legend("topright", legend=c("Minor allele carrier", "Wild type 
homozygous"), col=c("blue","red"), horiz=FALSE, y.intersp=0.9, bty='n', 
cex=0.8, lty=1, pt.cex = 1, title="Genotype group:") 
mtext("II", side=3, line=1, at=3) 
 
# log-rank test 
survdiff<-survdiff(Surv(RFS.year, cens.RFS) ~ Dicho, data=DGKB_pheno1) 
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